Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Gül, Ahmet ^a   Ozdogan, Huri ^b   Erer, Burak ^a   Ugurlu, Serdal ^b   Kasapcopur, Ozgur ^c   Davis, Nicole ^d   Sevgi, Serhan ^e  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Novartis Pharmaceutical Corporation   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; MONOCLONAL ANTIBODY; TUBULIN MODULATOR;

ADOLESCENT; ADULT; ANKLE FRACTURE; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL MEDITERRANEAN FEVER; HEADACHE; HIDRADENITIS; HUMAN; INJECTION SITE RASH; OPEN STUDY; PILOT STUDY; PRURITUS; QUALITY OF LIFE; SHORT FORM 36; TOOTH INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CHEMICALLY INDUCED; CHILD; DRUG ADMINISTRATION; DRUG RESISTANCE; FEMALE; MALE; METABOLISM; QUESTIONNAIRE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CHILD; COLCHICINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HEADACHE; HUMANS; MALE; PILOT PROJECTS; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; TUBULIN MODULATORS; VOMITING; YOUNG ADULT;

EID: 84940728830     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0765-4     Document Type: Article

References (14)

1. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol. 2009;27:621-68.
2. Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E, et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med. 1974;291:932-4.
3. Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med. 1974;291:934-7.
4. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314:1001-5.
5. Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Koné-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41:265-71.
6. Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R. IL-1β biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol. 2013;45:117-30.
7. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40:1879-85.
8. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416-25.
9. Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther. 2011;13:R202.
10. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396-406.
11. Ben-Chetrit E, Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum. 1991;20:241-6.
12. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351:659-64.
13. Lidar M, Yonath H, Shechter N, Sikron F, Sadetzki S, Langevitz P, et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev. 2012;12:72-6.
14. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157:533-41.